Comments
Loading...

Gain Therapeutics

GANXNASDAQ
Logo brought to you by Benzinga Data
$1.96
-0.13-6.18%
Pre-Market: Jan 29, 7:54 AM EDT
Consensus Rating1
Buy
Highest Price Target1
$10.00
Lowest Price Target1
$5.00
Consensus Price Target1
$7.88

Gain Therapeutics (NASDAQ:GANX) Stock, Analyst Ratings, Price Targets, Forecasts

Gain Therapeutics Inc has a consensus price target of $7.88 based on the ratings of 8 analysts. The high is $10 issued by Maxim Group on September 12, 2023. The low is $5 issued by B. Riley Securities on August 19, 2022. The 3 most-recent analyst ratings were released by Roth MKM, Roth MKM, and HC Wainwright & Co. on December 24, 2024, December 5, 2024, and November 25, 2024, respectively. With an average price target of $7.33 between Roth MKM, Roth MKM, and HC Wainwright & Co., there's an implied 273.98% upside for Gain Therapeutics Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
2
Aug 24
1
Sep 24
2
Oct 24
1
Nov 24
2
Dec 24
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
4.0
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Roth MKM
HC Wainwright & Co.
Oppenheimer
Chardan Capital
Oppenheimer

1calculated from analyst ratings

Analyst Ratings for Gain Therapeutics

Data brought to you by Benzinga APIs

FAQ

Q

What is the target price for Gain Therapeutics (GANX) stock?

A

The latest price target for Gain Therapeutics (NASDAQ:GANX) was reported by Roth MKM on December 24, 2024. The analyst firm set a price target for $7.00 expecting GANX to rise to within 12 months (a possible 256.98% upside). 17 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Gain Therapeutics (GANX)?

A

The latest analyst rating for Gain Therapeutics (NASDAQ:GANX) was provided by Roth MKM, and Gain Therapeutics maintained their buy rating.

Q

When was the last upgrade for Gain Therapeutics (GANX)?

A

There is no last upgrade for Gain Therapeutics

Q

When was the last downgrade for Gain Therapeutics (GANX)?

A

The last downgrade for Gain Therapeutics Inc happened on August 19, 2022 when B. Riley Securities changed their price target from $11 to $5 for Gain Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Gain Therapeutics (GANX)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Gain Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Gain Therapeutics was filed on December 24, 2024 so you should expect the next rating to be made available sometime around December 24, 2025.

Q

Is the Analyst Rating Gain Therapeutics (GANX) correct?

A

While ratings are subjective and will change, the latest Gain Therapeutics (GANX) rating was a maintained with a price target of $7.00 to $7.00. The current price Gain Therapeutics (GANX) is trading at is $1.96, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.